CY1109975T1 - Παρα-αλκυλ-υποκατεστημενα αμιδια ν-(4-υδροξυ-3-μεθοξυ-βενζυλο) κιναμμωμικου οξεος και η χρησιμοποιηση τους για την παρασκευη φαρμακων - Google Patents

Παρα-αλκυλ-υποκατεστημενα αμιδια ν-(4-υδροξυ-3-μεθοξυ-βενζυλο) κιναμμωμικου οξεος και η χρησιμοποιηση τους για την παρασκευη φαρμακων

Info

Publication number
CY1109975T1
CY1109975T1 CY20101100323T CY101100323T CY1109975T1 CY 1109975 T1 CY1109975 T1 CY 1109975T1 CY 20101100323 T CY20101100323 T CY 20101100323T CY 101100323 T CY101100323 T CY 101100323T CY 1109975 T1 CY1109975 T1 CY 1109975T1
Authority
CY
Cyprus
Prior art keywords
para
hydroxy
substituted
alkyl
paraska
Prior art date
Application number
CY20101100323T
Other languages
English (en)
Inventor
Sven Kühnert
Robert Frank
Ruth Jostock
Original Assignee
Grünenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grünenthal GmbH filed Critical Grünenthal GmbH
Publication of CY1109975T1 publication Critical patent/CY1109975T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/22—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)

Abstract

Η εφεύρεση αφορά παρα-αλκυλ-υποκατεστημένα αμίδια Ν-(4-υδροξυ-3-μεθοξυ-βενζυλο)κιναμμωμικού οξέος, μεθόδους για την παρασκευή τους, φάρμακα που περιέχουν τις ενώσεις αυτές καθώς και τη χρησιμοποίηση των ενώσεων αυτών για την παρασκευή φαρμάκων.
CY20101100323T 2004-08-12 2010-04-09 Παρα-αλκυλ-υποκατεστημενα αμιδια ν-(4-υδροξυ-3-μεθοξυ-βενζυλο) κιναμμωμικου οξεος και η χρησιμοποιηση τους για την παρασκευη φαρμακων CY1109975T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004039373A DE102004039373A1 (de) 2004-08-12 2004-08-12 Para-Alkyl-substituierte N-(4-Hydroxy-3-methoxy-benzyl)-zimtsäureamide und deren Verwendung zur Herstellung von Arzneimitteln
EP05777875A EP1778622B1 (de) 2004-08-12 2005-08-08 Para-alkyl-substituierte n-(4-hydroxy-3-methoxy-benzyl)-zimtsäeureamide und deren verwendung zur herstellung von arzneimitteln

Publications (1)

Publication Number Publication Date
CY1109975T1 true CY1109975T1 (el) 2014-09-10

Family

ID=35721367

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100323T CY1109975T1 (el) 2004-08-12 2010-04-09 Παρα-αλκυλ-υποκατεστημενα αμιδια ν-(4-υδροξυ-3-μεθοξυ-βενζυλο) κιναμμωμικου οξεος και η χρησιμοποιηση τους για την παρασκευη φαρμακων

Country Status (14)

Country Link
US (1) US7541495B2 (el)
EP (1) EP1778622B1 (el)
JP (1) JP4850834B2 (el)
AT (1) ATE455091T1 (el)
CA (1) CA2576274C (el)
CY (1) CY1109975T1 (el)
DE (2) DE102004039373A1 (el)
DK (1) DK1778622T3 (el)
ES (1) ES2339685T3 (el)
HR (1) HRP20100202T1 (el)
PL (1) PL1778622T3 (el)
PT (1) PT1778622E (el)
SI (1) SI1778622T1 (el)
WO (1) WO2006018406A1 (el)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8134004B2 (en) * 2006-07-11 2012-03-13 Pfizer Inc. Substituted N-bicyclicalkyl bicycliccarboxyamide compounds
US20080153845A1 (en) * 2006-10-27 2008-06-26 Redpoint Bio Corporation Trpv1 antagonists and uses thereof
GB0804213D0 (en) * 2008-03-06 2008-04-16 New Era Biotech Ltd A method of printing or preventing pain
KR101051085B1 (ko) 2008-11-24 2011-07-21 경희대학교 산학협력단 계피나무 추출물, 이의 분획물 또는 계피나무로부터 분리한트랜스―신남알데하이드를 유효성분으로 함유하는 파킨슨 질환 예방 및 치료용 조성물
US20140106046A1 (en) * 2011-06-30 2014-04-17 Firmenich Sa Taste modifying product
CN104884426A (zh) * 2012-12-28 2015-09-02 日本脏器制药株式会社 肉桂酰胺衍生物
CN107011313B (zh) * 2016-01-27 2021-11-30 天士力医药集团股份有限公司 取代桂皮酰胺衍生物在制备抗焦虑药物中的应用
WO2024048438A1 (ja) * 2022-09-01 2024-03-07 学校法人東京理科大学 ジアステレオマー調製方法及び固相光増感剤

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5726266B2 (el) * 1973-07-17 1982-06-03
JPS62281840A (ja) * 1986-05-29 1987-12-07 Otsuka Pharmaceut Co Ltd 桂皮酸誘導体の製造方法
WO1991016892A1 (en) * 1990-04-27 1991-11-14 Rorer International (Holdings), Inc. Styryl compounds which inhibit egf receptor protein tyrosine kinase
JPH0881429A (ja) * 1994-09-12 1996-03-26 Maruzen Petrochem Co Ltd 新規イミド化合物およびその製造方法
WO1997045400A1 (en) * 1996-05-24 1997-12-04 Neurosearch A/S Phenyl derivatives containing an acidic group, their preparation and their use as chloride channel blockers
WO1998020867A1 (en) * 1996-11-15 1998-05-22 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Pharmaceutical compositions containing vanilloid agonists in combination with vanilloid antagonists
AU6320998A (en) * 1997-02-21 1998-09-09 Bristol-Myers Squibb Company Benzoic acid derivatives and related compounds as antiarrhythmic agents
JPH10245357A (ja) * 1997-03-03 1998-09-14 Yakult Honsha Co Ltd フェニルプロペノン化合物及びこれを含有する医薬
DE19737327A1 (de) * 1997-08-27 1999-03-04 Haarmann & Reimer Gmbh Hydroxyzimtsäureamide hydroxysubstituierter aromatischer Amine
RU2003130221A (ru) * 2001-03-26 2005-04-10 Новартис АГ (CH) Сконденсированные пиридиновые производные, предназначенные для применения в качестве антагонистов ваниллоидного рецептора при лечении боли
WO2003092676A1 (en) * 2002-04-29 2003-11-13 The General Hospital Corporation Compositions and methods for preventing abuse of orally administered medications
JP2005225872A (ja) * 2004-01-15 2005-08-25 National Institute Of Advanced Industrial & Technology アディポネクチン産生増進剤

Also Published As

Publication number Publication date
JP4850834B2 (ja) 2012-01-11
DK1778622T3 (da) 2010-05-25
EP1778622B1 (de) 2010-01-13
PL1778622T3 (pl) 2010-06-30
JP2008509199A (ja) 2008-03-27
CA2576274C (en) 2013-10-08
WO2006018406A1 (de) 2006-02-23
HRP20100202T1 (hr) 2010-05-31
ES2339685T3 (es) 2010-05-24
EP1778622A1 (de) 2007-05-02
ATE455091T1 (de) 2010-01-15
SI1778622T1 (sl) 2010-04-30
DE502005008878D1 (de) 2010-03-04
US7541495B2 (en) 2009-06-02
DE102004039373A1 (de) 2006-02-23
CA2576274A1 (en) 2006-02-23
PT1778622E (pt) 2010-03-31
US20070208083A1 (en) 2007-09-06

Similar Documents

Publication Publication Date Title
CY1109975T1 (el) Παρα-αλκυλ-υποκατεστημενα αμιδια ν-(4-υδροξυ-3-μεθοξυ-βενζυλο) κιναμμωμικου οξεος και η χρησιμοποιηση τους για την παρασκευη φαρμακων
CY1116754T1 (el) Παραγωγα νιτροκατεχολης ως αναστολεις της comt
MY142589A (en) Benzimidazole derivatives : preparation and pharmaceutical applications
EA200900959A1 (ru) Ингибиторы мек
BRPI0508051A (pt) derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes
EA200700035A1 (ru) Сульфаматные и сульфамидные производные для лечения эпилепсии и родственных di sorders
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
ME00954B (me) Aminoheterociklični spojevi
SE0301700D0 (sv) Novel compounds
TR200201094T2 (tr) Farmasötik maddeler olarak bisiklik amino asitler
EA200700333A1 (ru) Терапевтические применения ингибиторов rtp801
EA200800172A1 (ru) 2,4-диаминопиримидины как ингибиторы aurora
BRPI0409109A (pt) novos compostos
CL2004001165A1 (es) Compuestos derivados de anilina y difenilamino n-sustituidos; inhibidores de las enzimas pde4; composicion farmaceutica; y su uso para el tratamiento de desordenes cognitivos.
ATE504580T1 (de) Malonsäureamidderivate als inhibitoren von g- sekretase zur behandlung von alzheimer-krankheit
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
MX2010002938A (es) Derivados de (3-hidroxi-4-amino-butan-2-il)-3-(2-tiazol-2-il-pirro lidin-1-carbonil)benzamida y compuestos relacionados como inhibidores de beta-secretasa para tratar enfermedad de alzheimer.
DE60318839D1 (de) 2,6-chinolinyl- und 2,6-naphthylderivate und deren verwendungen zur behandlung von vla-4 bezogenen krankheiten
MX2009014001A (es) Derivados de isoxazol-imidazol.
SE0403171D0 (sv) New compounds
BRPI0417858A (pt) composto, composição farmacêutica, e, uso de uma composição farmacêutica
BRPI0411864A (pt) combinação de inibidores de src quinase e agentes quimioterápicos para o tratamento de doenças proliferativas
TW200730512A (en) Novel compounds
ATE466007T1 (de) 5-substituierte indol-2-carbonsäureamidderivate
EA200701856A1 (ru) Тетрагидропиридоазепин-8-оны и родственные соединения для лечения шизофрении